Abstract
No public abstract is available from the verified source records.
Cyril Roussel-Simonin, Elie Rassy
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
openalex
Confidence 95%
unpaywall
Confidence 95%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
The rising tides of cancers among young adults
10.1016/j.esmoop.2025.105553 · 2025
The impact of young age at diagnosis (age <40 years) on prognosis varies by breast cancer subtype: a U.S. SEER database analysis
10.1016/j.breast.2021.12.006 · 2022
10.2908/tps00017
10.2908/tps00017 · 2025
Interrupting endocrine therapy to attempt pregnancy after breast cancer
10.1056/nejmoa2212856 · 2023
Pregnancy-associated cancer: a U.S. population-based study
10.1089/jwh.2018.6962 · 2019
Pregnancy-associated breast cancer: key concepts for optimizing diagnosis and treatment
10.1200/op-24-00867 · 2025
ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC)
10.1016/j.annonc.2023.08.001 · 2023
Pregnancy history, recency of childbirth, and outcomes in young women with early- stage breast cancer
10.1093/jnci/djag152 · 2026
The prognosis of women diagnosed with breast cancer before, during and after pregnancy: a meta-analysis
10.1007/s10549-016-3989-3 · 2016
Comprehensive review of pregnancy associated breast cancer: clinical features, molecular characteristics and novel therapies
datacite
Confidence 0%
10.1016/j.ejca.2026.116230 · 2026
Pembrolizumab for early triple-negative breast cancer
10.1056/nejmoa1910549 · 2020
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial
10.1016/j.annonc.2025.10.019 · 2026
Trastuzumab deruxtecan in residual HER2-positive early breast cancer
10.1056/nejmoa2514661 · 2026
Unresolved referenced work
2026
Tailoring targeted therapies for younger women with ER-positive early-stage breast cancer
10.1038/s41571-026-01120-7 · 2026
Survival of breast cancer patients after subsequent term pregnancy: “healthy mother effect
10.1016/s0002-9378(94)70290-x · 1994
Mammary intraepithelial lymphocytes and intestinal inputs shape T cell dynamics in lactogenesis
10.1038/s41590-025-02218-3 · 2025
Mammary intraepithelial lymphocytes promote lactogenesis and offspring fitness
10.1016/j.cell.2025.01.028 · 2025
Parity-induced changes to mammary epithelial cells control NKT cell expansion and mammary oncogenesis
10.1016/j.celrep.2021.110099 · 2021
Induction of senescence during postpartum mammary gland involution supports tissue remodeling and promotes postpartum tumorigenesis
10.1038/s43587-025-01058-y · 2026
Parity and lactation induce T-cell-mediated breast cancer protection
10.1038/s41586-025-09713-5 · 2026
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
10.1093/annonc/mdu450 · 2015
The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer
10.1016/j.cmet.2022.02.010 · 2022
No additional external references are available.